Lithuania vs Malaysia: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Lithuania
0.1%
in 2024
Malaysia
0.1%
in 2024
Lithuania rank
112th
Malaysia rank
112th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Lithuania
- Malaysia
How they compare
Lithuania currently reports 0.1% against 0.1% in Malaysia, a difference of 0.0%.
Across all 10 years both countries report, Malaysia has been ahead every year.
Lithuania ranks 112th and Malaysia ranks 112th of 215 countries.
Malaysia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Lithuania | Malaysia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.2% | 0.1% | Malaysia |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Lithuania or Malaysia?
- Lithuania, at 0.1% against 0.1% in Malaysia as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Lithuania and Malaysia?
- 0.0%, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Malaysia?
- 10 years are reported by both, from 2015 to 2024.
- How do Lithuania and Malaysia rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Lithuania ranks 112th and Malaysia ranks 112th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.